Keymed Biosciences Announces Strong Interim Results for 2025 with Accelerated Commercialization and R&D Momentum Keymed Biosciences reports impressive interim results for 2025, showcasing accelerated commercialization and significant R&D advancements on various fronts.

Keymed Biosciences Announces Strong Interim Results for 2025 with Accelerated Commercialization and R&D Momentum #China #Chengdu #Stapokibart #Keymed #R&D_Progress

Groundbreaking Phase III Results of Stapokibart for Treating Seasonal Allergic Rhinitis Published in Nature Medicine Keymed's Stapokibart, an IL-4Rα monoclonal antibody, shows promising results in treating moderate-to-severe seasonal allergic rhinitis, as published in Nature Medicine.

Groundbreaking Phase III Results of Stapokibart for Treating Seasonal Allergic Rhinitis Published in Nature Medicine #China #Chengdu #Stapokibart #Allergic_Rhinitis #Keymed

Keymed Biosciences Receives Approval for Stapokibart Treatment of Seasonal Allergic Rhinitis Keymed Biosciences announces the approval of Stapokibart by China's NMPA for treating seasonal allergic rhinitis, showcasing significant clinical benefits.

Keymed Biosciences Receives Approval for Stapokibart Treatment of Seasonal Allergic Rhinitis #China #Chengdu #Stapokibart #Keymed #Allergy_Treatment